A novel antidiabetic drug, troglitazone—reason for hope and concern
H Imura - New England Journal of Medicine, 1998 - Mass Medical Soc
H Imura
New England Journal of Medicine, 1998•Mass Medical SocType II (non-insulin-dependent) diabetes mellitus is characterized by insulin resistance,
increased hepatic glucose production, and impaired secretion of insulin by pancreatic beta
cells. Although the primary defect underlying these abnormalities is still not known, previous
longitudinal studies have indicated that insulin resistance precedes any evidence of glucose
intolerance in most patients. The goal of oral therapy with antidiabetic drugs is to lower
blood glucose concentrations toward normal by improving the pathophysiologic …
increased hepatic glucose production, and impaired secretion of insulin by pancreatic beta
cells. Although the primary defect underlying these abnormalities is still not known, previous
longitudinal studies have indicated that insulin resistance precedes any evidence of glucose
intolerance in most patients. The goal of oral therapy with antidiabetic drugs is to lower
blood glucose concentrations toward normal by improving the pathophysiologic …
Type II (non-insulin-dependent) diabetes mellitus is characterized by insulin resistance, increased hepatic glucose production, and impaired secretion of insulin by pancreatic beta cells. Although the primary defect underlying these abnormalities is still not known, previous longitudinal studies have indicated that insulin resistance precedes any evidence of glucose intolerance in most patients.
The goal of oral therapy with antidiabetic drugs is to lower blood glucose concentrations toward normal by improving the pathophysiologic abnormalities. Several classes of drugs are now available for the management of type II diabetes mellitus. The oldest are the sulfonylurea compounds. Although they may have some extrapancreatic actions, . . .
The New England Journal Of Medicine